# 2025-08449: SKINVIVE Patent Extension Gets Its FDA Review Period

2025-08449, Determination of Regulatory Review Period for Purposes of Patent Extension; SKINVIVE, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-05-14 (as of 2026-10-20).

- Canonical: https://policyrisk.com/federal-register/2025-08449
- As of: 2026-10-20
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08449
- Title: Determination of Regulatory Review Period for Purposes of Patent Extension; SKINVIVE
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 20471
- Published: 2025-05-14
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-10-20

## In one line

SKINVIVE Patent Extension Gets Its FDA Review Period

## Summary

The FDA has set the official review period for SKINVIVE, a medical device, so its patent holder can apply for extra patent time. If you think the dates are wrong or want to challenge the patent holder’s effort during review, you have until mid-2025 to speak up. This affects the company behind SKINVIVE and could impact how long they keep exclusive rights to their invention.

## Abstract

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SKINVIVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-08449 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/14/2025-08449/determination-of-regulatory-review-period-for-purposes-of-patent-extension-skinvive)
- [2025-08449 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-14/pdf/2025-08449.pdf)

## Related
- [Previous: 2025-08448, Proposed Collection; Comment Request; Extension: Rule 18a-3](https://policyrisk.com/federal-register/2025-08448)
- [Next: 2025-08450, Determination of Regulatory Review Period for Purposes of Patent Extension; EPK…](https://policyrisk.com/federal-register/2025-08450)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08449 (as of 2026-10-20).